



# SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號 : 9989)

## NOTIFICATION LETTER 通知信函

Dear Shareholders (附註1),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

- Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The Board of Directors of the Company has decided to convene the 2024 First Extraordinary General Meeting of the Company on December 27, 2023 at the HKECC's e-meeting system. You may access the Company's circular by clicking the e-meeting link ( ) on the following website: [www.hkex.com.hk](#).

If you wish to receive the circular of the Company, you may apply for the Company's circular (附註2) of the Company, please fill in the Request Form (附註3) (which may be downloaded from the e-meeting system) and send it back to the Secretary of the Company (c/o The Listing Section of the Hong Kong Share Registrar) by email or by post to the Registered Office of the Company in Hong Kong. The address of the Hong Kong Share Registrar is 17/F, Finance Centre, 16 Harbour Road, Hong Kong.

Unless otherwise specified, the Company's circular of the Company shall be free of charge.

Should you have any enquiries, please contact the Secretary of the Company at the Hong Kong Share Registrar (852) 2980 1333 from 9:00 am to 6:00 pm, Monday to Friday, excluding public holidays.

Yours faithfully,  
Faded name  
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.  
Li Li  
Chairman

Note 1: The e-meeting system is the e-meeting system of the Company, which is operated by the Company's e-meeting system (CCASS) and the HKECC's e-meeting system. The Secretary of the Company is Li Li, who is also the Chairman of the Company. If you wish to receive the circular of the Company, please contact the Secretary of the Company.

Note 2: The Company's circular (the "Corporate Communications") of the Company may be accessed by clicking the e-meeting link on the following website: [www.hkex.com.hk](#). (a) e-meeting system; (b) e-meeting system; (c) e-meeting system; (d) e-meeting system; (e) e-meeting system.

致非登記股份持有人(附註1):

深圳市海普瑞藥業集團股份有限公司(「本公司」)  
- 2024年第一次臨時股東大會通函、通告及代表委任表格(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件中、英文版本現已上載於本公司網站 [www.hkex.com.hk](#) 及香港交易所披露易網站 [www.hkex.com.hk](#)，歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件(附註2)之印刷本，請填妥在本信函背面的申請表格(「申請表格」)(該表格亦可於上述網站下載)，並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄)；否則，請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司(「香港股份登記處」)寄回本公司，香港股份登記處的地址為香港夏愨道16號遠東金融中心17樓。

抽吳頌脫露 蒿郎鐘合 出掉蛸 掉普枯 鵲駟 儲 豈 冉

Request Form 申請表格

To: Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") (Stock Code: 9989) c/ T c I e e S e l e c t e d ( e H o n g K o n g S h a r e R e g i s t r a r ) 17/F, Fa Ea F a c e C e e, 16 H a c, R a d, H K

致: 深圳市海普瑞藥業集團股份有限公司 (「本公司」) (股份代號: 9989) 經卓佳證券登記有限公司 (「香港股份登記處」) 香港夏慤道16號 遠東金融中心17樓

I/We would like to receive the Company's communication materials for the Company's financial year ending on the date of ...

(Please tick ONLY ONE (X) for each of the following) (請從下列選擇中, 僅在其中一個空格內劃上「X」號)

I would like to receive the Company's communication materials (including the Company's financial year ending on the date of ...) in electronic form only. I have already received the Company's communication materials (including the Company's financial year ending on the date of ...) in printed form. (附註2); OR

I would like to receive the Company's communication materials (including the Company's financial year ending on the date of ...) in electronic form only. I have not yet received the Company's communication materials (including the Company's financial year ending on the date of ...) in printed form. OR

I would like to receive the Company's communication materials (including the Company's financial year ending on the date of ...) in electronic form only. I have not yet received the Company's communication materials (including the Company's financial year ending on the date of ...) in printed form. OR

I would like to receive the Company's communication materials (including the Company's financial year ending on the date of ...) in electronic form only. I have not yet received the Company's communication materials (including the Company's financial year ending on the date of ...) in printed form.

Name of Non-Registered Holder ( )# 非登記持有人姓名#

Signature 簽名

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Address# 地址#

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact Telephone# 聯絡電話號碼

Date 日期

# If you have downloaded the Application Form from the Company's website or the HKEX website, please complete the relevant information.

Notes 附註:

- 1. Please complete all the information. 請閣下清楚填寫所有資料。
2. After selecting the relevant option, please indicate your consent to receive the Company's communication materials in electronic form only. 在選擇本項後, 閣下已明示同意放棄收取公司通訊文件印刷本的權利。
3. The relevant information should be provided in the English Block Letters (E-BLOCK LETTERS) and the Chinese Block Letters (C-BLOCK LETTERS). 本申請表格應由本公司非登記股份持有人填寫。該等人士的股份存放於中央結算及交收系統(中央結算系統), 並且他們已經通過香港中央結算有限公司通知本公司, 希望收到本公司通訊文件。
4. After selecting the relevant option, please indicate your consent to receive the Company's communication materials in electronic form only. 如在本申請表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確, 則有關表格將會作廢。
5. For any clarification, please contact the Company's Share Registrar. 為免存疑, 本公司恕不接受此表格上提供的任何其他指示。任何在此表格上提供的額外指示將視作無效。
6. You will receive the Company's communication materials (including the Company's financial year ending on the date of ...) in electronic form only. 閣下有權隨時發出合理時間的書面通知通過香港股份登記處予本公司, 要求更改本公司通訊文件之語言版本或收取方式。
\* The Company's communication materials for the 2024 Annual General Meeting, Notice and Proxy Form. 本公司此次公司通訊文件指2024年第一次臨時股東大會通函、通告及代表委任表格。
\*\* The Company's communication materials for the 2024 Annual General Meeting, Notice and Proxy Form. 本公司此次公司通訊文件指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件, 其中包括但不限於: (a) 年度報告及財務摘要報告(如適用); (b) 中期報告及中期摘要報告(如適用); (c) 會議通告; (d) 上市文件; (e) 通函; 及(f) 委任代表表格。

Please affix the postage stamp here. No postage is necessary if posted in Hong Kong.

當閣下寄回本申請表格時, 請將郵寄標籤剪貼於信封上。如在本港投寄, 閣下無需支付郵費或貼上郵票。

Mailing Label 郵寄標籤

Tricor Investor Services Limited 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼: 10 GPO Hong Kong 香港